Osimertinib versus gefitinib followed by osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE trial

被引：0
|
作者：
Masip, J. Remon [1 ]
Besse, B. [1 ]
Aix, S. Ponce [2 ]
Perez, A. Callejo [3 ]
Al-Rabi, K. [4 ]
Caro, R. Bernabe [5 ]
Greillier, L. [6 ]
Tarruella, M. Majem [7 ]
Aransay, N. Reguart [8 ]
Monnet, I. [9 ]
Cousin, S. [10 ]
Lopez, P. Garrido [11 ]
Robinet, G. [12 ]
Campelo, R. Garciaprime [13 ]
Flandin, A-C. Madroszyk [14 ]
Mazieres, J. [15 ]
Curcio, H. [16 ]
Pretzenbacher, Y. [17 ]
Dingemans, A-M. C. [18 ]
Dziadziuszko, R. [19 ]
机构：
[1] Inst Gustave Roussy, Oncol Dept, Villejuif, France
[2] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain
[3] Vall dHebron Univ Hosp, Oncol Dept, Barcelona, Spain
[4] KHCC King Hussein Canc Ctr, Med Oncol & Hematol Dept, Amman, Jordan
[5] Hosp Univ Virgen Rocio, Seville, Spain
[6] Hop St Marguerite Assistance Publ Hop Marseille, Multidisciplinary Oncol & Therapeut Innovat, Marseille, France
[7] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[8] Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain
[9] Chi Creteil, Creteil, France
[10] Inst Bergonie, Early Phase Trials, Bordeaux, France
[11] Hosp Univ Ramon & Cajal, Med Oncol Dept, Madrid, Spain
[12] CHRU Brest Hop Morvan, Brest, France
[13] CHUAC Complexo Hosp Univ A Coruna, La Coruna, Spain
[14] IPC Inst Paoli Calmettes, Marseille, France
[15] Ctr Hosp Univ Toulouse, Thorac Oncol Dept, Hop Larrey, Toulouse, France
[16] Ctr Francois Baclesse, Oncol Dept, Caen, France
[17] EORTC AISBL IVZW European Org Res & Treatment Can, Stat, Brussels, Belgium
[18] Erasmus MC Univ, Pulmonol Dept, Med Ctr, Rotterdam, Netherlands
[19] Med Univ Gdansk, Oncol & Radiotherapy Dept, Gdansk, Poland
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1O
引用
收藏
页码：S35 / S35
页数：1
相关论文
共 50 条
  • [41] Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer
    Patil, Tejas
    Pacheco, Jose M.
    Dimou, Anastasios
    Purcell, William T.
    Rossi, Candice
    Bunn, Paul A.
    Doebele, Robert C.
    Camidge, D. Ross
    Ferrigno, Lisa
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [42] Modeling the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer patients.
    Lemmon, Christopher
    Zabor, Emily Craig
    Pennell, Nathan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)
    Ma, Y.
    Zhao, H.
    Zhao, Y.
    Cheng, Y.
    Cui, J.
    Liu, G.
    Xiong, D.
    Zhang, J.
    Xu, L.
    Yu, J.
    Men, L.
    Liang, E.
    Yang, D.
    Zhang, L.
    Zhai, Y.
    ANNALS OF ONCOLOGY, 2023, 34
  • [44] Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC).
    Zhang, Li
    Zhao, Hongyun
    Zhao, Yanqiu
    Cheng, Ying
    Cui, Jiuwei
    Ma, Yuxiang
    Yang, Chen
    Zhang, Jie
    Xu, Liang
    Yu, Juan
    Men, Lichuang
    Liang, Zhiyan
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
    Paulina Bracht, Jillian Wilhelmina
    Karachaliou, Niki
    Berenguer, Jordi
    Pedraz-Valdunciel, Carlos
    Filipska, Martyna
    Codony-Servat, Carles
    Codony-Servat, Jordi
    Rosell, Rafael
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2019, 15 (12): : 2607 - 2614
  • [46] Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis
    Wen, Lei
    Zhen, Junjie
    Shan, Changguo
    Lai, Mingyao
    Hong, Weiping
    Wang, Hui
    Ye, Mingting
    Yang, Yanying
    Li, Shaoqun
    Zhou, Zhaoming
    Zhou, Jiangfen
    Hu, Qingjun
    Li, Juan
    Tian, Xuwei
    Chen, Longhua
    Cai, Linbo
    Xie, Zhanhong
    Zhou, Cheng
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2023, 28 (01)
  • [47] Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR-mutant non-small cell lung cancer
    Qin, Qiong
    Li, Xiaoqing
    Liang, Xingmei
    Zeng, Lili
    Wang, Jing
    Sun, Linlin
    Zhong, Diansheng
    THORACIC CANCER, 2021, 12 (11) : 1708 - 1715
  • [48] Osimertinib Delays but Not Prevents Central Nervous System Metastasis in EGFR-Mutant Advanced Non-Small Cell Lung Cancer
    Zhou, Y.
    Zhu, Z.
    Ni, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S591 - S591
  • [49] Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
    Cho, Byoung Chul
    Kim, Dong-Wan
    Spira, Alexander I.
    Gomez, Jorge E.
    Haura, Eric B.
    Kim, Sang-We
    Sanborn, Rachel E.
    Cho, Eun Kyung
    Lee, Ki Hyeong
    Minchom, Anna
    Lee, Jong-Seok
    Han, Ji-Youn
    Nagasaka, Misako
    Sabari, Joshua K.
    Ou, Sai-Hong Ignatius
    Lorenzini, Patricia
    Bauml, Joshua M.
    Curtin, Joshua C.
    Roshak, Amy
    Gao, Grace
    Xie, John
    Thayu, Meena
    Knoblauch, Roland E.
    Park, Keunchil
    NATURE MEDICINE, 2023, 29 (10) : 2577 - +
  • [50] Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
    Byoung Chul Cho
    Dong-Wan Kim
    Alexander I. Spira
    Jorge E. Gomez
    Eric B. Haura
    Sang-We Kim
    Rachel E. Sanborn
    Eun Kyung Cho
    Ki Hyeong Lee
    Anna Minchom
    Jong-Seok Lee
    Ji-Youn Han
    Misako Nagasaka
    Joshua K. Sabari
    Sai-Hong Ignatius Ou
    Patricia Lorenzini
    Joshua M. Bauml
    Joshua C. Curtin
    Amy Roshak
    Grace Gao
    John Xie
    Meena Thayu
    Roland E. Knoblauch
    Keunchil Park
    Nature Medicine, 2023, 29 : 2577 - 2585
12345